Filovirus emergence and vaccine development: A perspective for health care practitioners in travel medicine

Travel Medicine and Infectious Disease

Volumn 9, Issue 3, 2011, Pages 126-134

  Sarwar, Uzma N ^a   Sitar, Sandra ^a   Ledgerwood, Julie E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Filovirus vaccines; Glycoprotein antigen; Imported Marburg infection

Indexed keywords

ALPHA INTERFERON; EBOLA VACCINE; MARBURG VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ABDOMINAL PAIN; AFRICA; ANOREXIA; ANTIVIRAL THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; CHILL; DIARRHEA; DNA IMMUNIZATION; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ELECTRON MICROSCOPY; EMPORIATRICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FLUID THERAPY; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; IMMUNE RESPONSE; IMMUNITY; KIDNEY FAILURE; MALAISE; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; MORBIDITY; MORTALITY; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; PATHOGENESIS; PHARYNGITIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; VACCINATION; VIRUS TRANSMISSION;

EID: 79958849357     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2010.05.003     Document Type: Article

References (57)

1. Bray M. Epidemiology, pathogenesis and clinical manifestations of Ebola and Marburg hemorrhagic fever. Uptodate 2009 July 28.
2. Murdoc D. Diseases potentially acquired by travel to Sub Saharan Africa. Uptodate 2008 September 8.
3. Bray M, Murphy FA. Filovirus research: knowledge expands to meet a growing threat. J Infect Dis 2007;196(Suppl. 2): S438-43.
4. Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis 2001;33:1707-12. (Pubitemid 33044538)
5. Ebola hemorrhagic fever: known cases and outbreaks of ebola hemorrhagic fever in chronological order. CDC; 2009 August 26.
6. Special pathogens branch. Outbreak postings. CDC; 2009 December 23.
7. Bermejo M, Rodriguez-Teijeiro JD, Illera G, Barroso A, Vila C, Walsh PD. Ebola outbreak killed 5000 gorillas. Science 2006; 314:1564. (Pubitemid 44907142)
8. Thacker PD. An Ebola epidemic simmers in Africa: in remote region, outbreak shows staying power. JAMA 2003;290:317-9. (Pubitemid 37430510)
9. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575-6. (Pubitemid 41740557)
10. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009;5:e1000536.
11. CDC. Imported case of Marburg hemorrhagic fever-Colorado 2008. MMWR - morbidity & mortality weekly report; 2009 December 18. p. 1377-81.
12. Stroher U, Feldmann H. Progress towards the treatment of ebola haemorrhagic fever. Expert Opin Investig Drugs 2006;15: 1523-35. (Pubitemid 44848976)
13. Marburg hemorrhagic fever. WHO; 2008, July.
14. Bray M. Defense against filoviruses used as biological weapons. Antivir Res 2003;57:53-60. (Pubitemid 36254721)
15. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999;179(Suppl. 1):S87-91.
16. Fisher-Hoch SP. Lessons from nosocomial viral haemorrhagic fever outbreaks. Br Med Bull 2005;73-74:123-37. (Pubitemid 43020363)
17. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges- Courbot MC, Lansoud-Soukate J. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000;355: 2210-5. (Pubitemid 30394329)
18. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis 2000;5:5-7.
19. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud- Soukate J, Debre P. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5:423-6. (Pubitemid 29180581)
20. Schnittler HJ, Feldmann H. Viral hemorrhagic fever - a vascular disease? Thromb Haemost 2003;89:967-72.
21. Saijo M, Niikura M, Ikegami T, Kurane I, Kurata T, Morikawa S. Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins. Clin Vaccine Immunol 2006;13:444-51. (Pubitemid 44044829)
22. Bray M. Diagnosis and treatment of Ebola and Marburg hemorrhagic fever. Uptodate 2008 September 30.
23. Bray M, Paragas J. Experimental therapy of filovirus infections. Antivir Res 2002;54:1-17. (Pubitemid 34219170)
24. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999;179:S18-23.
25. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999;179(Suppl. 1):S224-34.
26. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, Young HA, Formenty P, Fritz EA. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007; 196(Suppl. 2):S372-81.
27. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003;362:1953-8. (Pubitemid 37548417)
28. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T. Recombinant human activated protein C for the post exposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007;196(Suppl. 2):S390-9.
29. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA. Post exposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006;367:1399-404.
30. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F. Recombinant vesicular stomatitis virus vector mediates post exposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008;82: 5664-8. (Pubitemid 351705275)
31. Slenczka W, Klenk HD. Forty years of marburg virus. J Infect Dis 2007;196(Suppl. 2):S131-5.
32. Balter M. Emerging diseases. On the trail of Ebola and Marburg viruses. Science 2000;290:923-5.
33. Borchert M, Boelaert M, Sleurs H, Muyembe-Tamfum JJ, Pirard P, Colebunders R. Viewpoint: filovirus haemorrhagic fever outbreaks: much ado about nothing? Trop Med Int Health 2000;5:318-24.
34. Peters CJ. Marburg and Ebola - arming ourselves against the deadly filoviruses. N Engl J Med 2005;352:2571-3. (Pubitemid 41007840)
35. Pourrut X, Kumulungui B, Wittmann T, Moussavou G, Delicat A, Yaba P. The natural history of Ebola virus in Africa. Microbes Infect 2005;7:1005-14. (Pubitemid 40982668)
36. Known cases and outbreaks of marburg hemorrhagic fever, in chronological order. CDC; 2009, July 31st.
37. Bausch DG, Borchert M, Grein T, Roth C, Swanepoel R, Libande ML. Risk factors for marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis 2003;9: 1531-7.
38. Dutch tourist infected with Marburg Virus. Environment NIf- PHat; 2008 July 10.
39. Timen A, Koopmans MP, Vossen AC, van Doornum GJ, Gunther S, van den Berkmortel F. Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis 2009;15:1171-5.
40. Case of Marburg hemorrhagic fever imported into the Netherlands from Uganda. WHO; 2008 July 10.
41. Barnes M, Fuijita NK. Marburg virus in a Wheat Ridge Colorado hospital 2008. Bethesda: Maryland National Institutes of Health; 2009, June 22.
42. Clinician outreach and communication activity update for February 2009. CDC; 2009 February.
43. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005;23:3033-42. (Pubitemid 40462443)
44. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004;22: 3495-502. (Pubitemid 39078769)
45. Bausch DG, Geisbert TW. Development of vaccines for Marburg hemorrhagic fever. Expert Rev Vaccines 2007;6:57-74. (Pubitemid 46237547)
46. Geisbert TW, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev Vaccines 2003;2:777-89. (Pubitemid 37541564)
47. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002;8:503-7. (Pubitemid 34533328)
48. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006;13: 1267-77. (Pubitemid 46768881)
49. Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol 2003;77: 9733-7. (Pubitemid 37122053)
50. Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM. Chimeric human parainfluenza virus bearing the ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against ebola virus challenge. Virology 2009; 383:348-61.
51. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009;83:7296-304.
52. Geisbert T, Daddario KM, Lewis MG, Geisbert J, Grolla A, Leung A. Vesicular stomatitis virus-based ebola vaccine is well tolerated and protects immunocompromised nonhuman primates. PLoS Med 2008;4.
53. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605-9.
54. Graham B. Safety and immunogenicity of a multiclade HIV-1 recombinant adenovirus vacine boost in prior recipients of a multiclade HIV-1 DNA vaccine (paper #15(827P)) AIDS Vaccine 2005. Montreal: Canada; 2005.
55. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424: 681-4. (Pubitemid 36987993)
56. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008;15:460-7. (Pubitemid 351967082)
57. Ledgerwood JE, Costner, P, Desai, N, Holman, L, Enama, ME, Yamshchikov, et al. A replication defective recombinant Ad5 vaccine expressing ebola GP is safe and immunogenic in healthy Adults, submitted for publication.